Abstract
Oral administration of AG3340, a novel metalloprotease (MMP) inhibitor, suppresses the growth of human colon adenocarcinoma (COLO-320DM) tumors in vivo (Proc Am Assoc Cancer Res 39: 2059, 1998). In this report, we tested the hypothesis that the growth inhibition of these tumors is associated with maintaining minimum effective plasma concentrations of AG3340. Nude mice were given a total oral daily dose of 25 or 200 mg/kg; 6.25 mg/kg was given four times per day (QID) (25 mg/kg/day), and 100 mg/kg was given in two daily doses (BID) (200 mg/kg/day). Peak plasma concentrations (Cmax) of 83 ± 43 (mean ± SD) and 1998 ± 642 ng/ml were detected 30 min after a single dose with 6.25 mg/kg and 100 mg/kg AG3340, respectively. AUC(0-24 h) values estimated from dosing with 25 and 200 mg/kg/day AG3340 were 672 and 10882 ng*h/ml, respectively. Importantly, both regimen inhibited tumor growth equivalently (74 to 82%). Efficacy was also compared at a total daily dose of 25 mg/kg by giving AG3340: QID (6.25 mg/kg per dose), BID (12.5 mg/kg per dose), and once daily (25 mg/kg per dose). The Cmax of these regimens was 83 ± 43, 287 ± 175 and 462 ± 495 ng/ml, respectively. AG3340 did not inhibit tumor growth with the latter two regimens. The efficacy of 6.25 mg/kg QID (25 mg/kg/day) was superior to the efficacy of 25 mg/kg BID (50 mg/kg/day), substantiating the independence of efficacy from the total daily dose and Cmax. Expectedly, peak to trough fluctuations were significantly smaller with the QID regimen than with BID and QD dosing. After 24 h, the trough was greater than 1 ng/ml with QID dosing but was less than 1 ng/ml after QD and BID dosing. These results suggest that the antitumor efficacy of AG3340 was associated with maintaining minimum effective plasma concentrations of AG3340 and demonstrate that the antitumor efficacy of AG3340 was independent of the total daily dose, peak plasma concentration, and drug exposure in this tumor model.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Levy DE, Ezrin AM: Matrix metalloprotease inhibitor drugs. In: Emerging Drugs: The Prospective for Improved Medicines. Ashley Publications Ltd., 1997
Wojtowicz-Praga SM, Dickson RB, Hawkins M: Matrix metalloprotease inhibitors. Invest New Drugs 15: 61-75, 1997
Morphy JR, Millican T, Porter JR: Matrix metalloprotease inhibitors: current status. Curr Med Chem 2: 743-762, 1995
Ray JM, Stetler-Stevenson WG: Matrix metalloproteinases and malignant disease: recent developments. Exp Opin Invest Drugs 5: 323-335, 1996
Hua J, Muschel RJ: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56: 5279-5284, 1996
Brown PD: Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol 14: 1-10, 1997
Bender SL: Structure-based design of MMP inhibitors: discovery and development of AG3340. 214th National Meeting of the American Chemical Society, Las Vegas, NV, 1997
Santos O, McDermott CD, Daniels RG, Appelt K: Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteases. Clin Exp Metastasis 15: 499-508, 1997
Shalinsky DR, Brekken J, Varki NV, Robinson SR, Daniels R, Kolis S, Bansal S, Zou H, Bender S, Zook S, Margosiak S, Wood AW, Webber S, Appelt K: Marked inhibition of the proliferation of human adenocarcinoma colon tumors in vivoby orally-administered AG3340, a novel matrix metalloproteinase inhibitor. Proc Am Assoc Cancer Res 39: A2059, 1998
Neri A, Goggin B, Kolis S, Brekken J, Khelemskaya N, Gabriel L, Robinson SR, Webber S, Wood AW, Appelt K, Shalinsky DR: Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in lung after IV-tail implantation in C57BL/6 mice. Proc Am Assoc Cancer Res 39: A2060, 1998
Price A, Rewcastle NB, Yong VW, Zhong QS, Brasher P, Morris MG, Spencer D, Edwards D, Appelt KA, Forsyth P: Marked inhibition of tumor growth in a malignant glioma tumor model by the novel, synthetic matrix metalloproteinase (MMP) inhibitor, AG3340. Proc Am Assoc Cancer Res 39: 2061, 1998
Shalinsky DR, Brekken J, Zou H, Bender S, Zook S, Appelt K, Webber S, Varki NV: Increased apoptosis in human androgen-independent prostatic PC-3 tumors following oral administration of a novel matrix metalloproteinase (MMP) inhibitor, AG3340, in male nude mice. Proc Am Assoc Cancer Res 39: A4400, 1998
Johnston MR, Mullen JBM, Pagura M, Appelt KA, Shalinsky DR: AG3340, a novel matrix metalloproteinase (MMP) inhibitor, inhibits the growth of human large cell lung cancer tumors orthotopically implanted into the lung of athymic nude rats. Proc Am Assoc Cancer Res 39: A2060, 1998
Collier MA, Yuen GJ, Bansal SK, Kolis S, Chew TG, Appelt K, Clendinin NJ: A Phase I study of the matrix metalloproteinase (MMP) inhibitor, AG3340 given in single doses to healthy volunteers. Proc Am Assoc Cancer Res 38: A1491, 1997
Quinn LA, Moore GE, Morgan RT, Woods LK: Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res 39: 4914-4924, 1979
Hibner B, Cad A, Flynn C, Casazza AM, Taraboletti G, Rieppi M, Giavazzi R: BAY 12-9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties. Proc Am Assoc Cancer Res 39: 2063, 1998
Krane SM: Is collagenase (matrix metalloproteinase-1) necessary for bone and other connective tissue remodeling? Clin Orthop 313: 47-53, 1995
Yocum S, Lopresit-Morrow L, Reeves L, Mitchell P: MMP-13 and MMP-1 expression in tissues of normal articular joints. Proc NYAS, Second Conference on Inhibition of Matrix Metalloproteinases: Therapeutic Applications. Tampa, FL, 10/21-24/98
Itoh T, Tanioka M, Yoshida H, Yoshida T, Nishimoto H, Itohara S: Reduced angiogenesis and tumor progression in gelatinase-A deficient mice. Cancer Res 58: 1048-1051, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shalinsky, D.R., Brekken, J., Zou, H. et al. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Invest New Drugs 16, 303–313 (1998). https://doi.org/10.1023/A:1006204901140
Issue Date:
DOI: https://doi.org/10.1023/A:1006204901140